Form 10-Q Sage Therapeutics, Inc. For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sage Therapeutics (SAGE) PT Lowered to $15 at Stifel
August 1, 2024 6:40 AM EDTStifel analyst Paul Matteis lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $15.00 (from $20.00) while maintaining a Hold rating.
The analyst comments "Zurzuvae continues to launch reasonably well in PPD, coming in a hair above consensus despite a significant inventory drawdown. Meanwhile... More
